Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir

Blood

Volumn 89, Issue 4, 1997, Pages 1334-1340

  Munshi, N C ^a   Govindarajan, R ^b   Drake, R ^b   Ding, L M ^b   Lyer, R ^b   Saylors, R ^b   Kornbluth, J ^b   Marcus, S ^b   Chiang, Y ^b   Ennist, D ^b   Kwak, L ^b   Reynolds, C ^b   Tricot, G ^b   Barlogie, B ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR;

ALLOGENEIC RESTRICTION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER INCIDENCE; CELL KILLING; GENETIC TRANSDUCTION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LONG TERMINAL REPEAT; LYMPHOCYTE CULTURE; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; SIGNAL TRANSDUCTION; SUICIDE GENE; SUPPRESSOR CELL; T LYMPHOCYTE;

EID: 0031049485     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.4.1334     Document Type: Article

References (36)

1. Bortin MM, Rimm AA: Increasing utilization of bone marrow transplantation. Transplantation 42:229, 1986
2. Gale RP, Champlin R: How does bone marrow transplant cure leukemia? Lancet 2:28, 1984
3. Bortin MM, Truitt RL, Rimm AA, Bach FH: Graft vs leukemia reactivity induced by alloimmunization without augmentation of graft-vs-host reactivity. Nature 281:490, 1979
4. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, Facon T, Granena A, Gore M, Gratwohl A, Lowenberg B, Nikoskelainen J, Reiffers J, Samson D, Verdonck L, Volin L: Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 325;1267, 1991
5. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Sanders J, Singer J, Stewart P, Thomas ED: Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720, 1989
6. Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C, Golan DE, Macklis RM, Tarbell NJ, Lynch E, Reichert TA, Blythman H, Bouloux C, Rappeport JM, Burakoff SJ, Weinstein HJ: Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78:2139, 1991
7. Soiffer RJ, Murray C, Mauch P, Anderson KC, Freedman AS, Rabinowe SN, Takvorian T, Robertson MJ, Spector N, Gonin R, Miller KB, Rudders RA, Freeman A, Blake K, Coral F, Nadler LM, Ritz J: Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol 10:1191, 1992
8. O'Reilly RJ: T-cell depletion and allogeneic bone marrow transplantation Semin Hematol 29:20, 1992
9. Hale G, Cobbold S, Waldmann H: T cell depletion with CAM-PATH-1 in allogeneic bone marrow transplantation. Transplantation 45:753, 1988
10. Patterson J, Prentice HG, Brennar MK, Gilmore M, Janossy G, Ivory K, Skeggs D, Morgan H, Lord J, Blacklock HA, Huffman AV, Apperly JF, Goldman JM, Burnett A, Gribben J, Alcorn M, Pearson C, McVickers I, Hann IM, Reid C, Wardle D, Gravett PJ, Bacigalupo A, Robertson AG, Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 63:221, 1986
11. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300: 1068, 1979
12. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, Bekkum DW, Champlin RE, Dicke KA, Holdman FJ, Good RA, Herzig RG, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120, 1991
13. Martin PJ, Clift RA, Fisher LD, Buckner CD, Hansen JA, Applebaum FR, Doney KC, Sullivan KM, Witherspoon RP, Storb R, Thomas ED: HLA-identicul marrow transplantation during accelerated-phase chronic myelogenous leukemia: Analysis of survival and remission duration. Blood 72:1978, 1988
14. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR, Arthur DC, Patton DF, Greenberg JS, Burke B, Ramsay NKC, McGlave P, Filiprovich AH: Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 71:1234, 1988
15. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM: Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520, 1988
16. Papadopoulos EB, Ladanvi M: Donor leukocyte infusions as treatment of Epstein-Barr virus lymphoproliferative disorders (EBV-LPD) in recipients of unrelated and related allogeneic transplants. Blood 82:214a, 1993 (suppl 1. abstr)
17. Sanders JE, Buckner CD, Clift RA, Fefer A, McGuffin R, Storb R, Appelbaum F, Bensinger W, Beatty P, Doney K: Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. Bone Marrow Transplant 3:11, 1988
18. Bär BM, Shattenberg EJ, Clemm C , Mensink EJ, Geurts Van Kessel A, Smetsers TF, Knops GH, Linders EHP, De Witte T: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation J Clin Oncol 11:513, 1993
19. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Ruinen P, Horowitz MM, Flomenberg N: Salvage immunotherapy using donor leukocyte infu-sions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310, 1993
20. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P, Sanders JE, Singer J, Thomas ED: Graft-vs-host disease as adoptive immunotherapy in patients with advanced hematological neoplasms. N Engl J Med 320:828, 1989
21. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Eng J Med 330:100, 1994
22. Borani M, Tonkovi I: Time pattern of the antileukemic effect of graft-versus-host reaction. Cancer Res 31:1140, 1971
23. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase gene: Paradigm for a prospective cancer control strategy. Cancer Res 46:5276, 1986
24. Borrelli E, Heyman R, Hsi M, Evans RM: Targetting of an inducible toxic phenotype in animal cells. Proc Acad Sci USA 85:7572, 1988
25. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1550, 1992
26. Faulds D, Heel RC: Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39:597, 1990
27. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN: The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274, 1993
28. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462, 1990
29. Tricot G, Vesole D, Jagannath S, Hilton J, Munshi N, Barlogie B: Graft-versus-myeloma effect: Proof of principle. Blood 87:1196, 1996
30. Tiberghien P, Raynolds CW, Keller J, Spence S, Deschaseaux M, Certoux J-M, Contassot E, Murphy WJ, Lyons R, Chiang Y, Hervé P, Longo DL, Ruscetti FW: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: An approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 84:1333, 1994
31. Bordignon C, Bonini C, Verzeletti S, Nobili N, Maggioni D, Traversari C, Giavazzi R, Servida P, Zappone E, Benazzi E: Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 6:813, 1995
32. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller D, Bleaese RM, Anderson F: Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570, 1990
33. + HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplants. Hum Gene Ther 3:319, 1992
34. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, O'Reilly RJ: Adaptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: Is T cell dose important in determining biological response? Bone Marrow Transplant 15:591, 1995
35. Papadopoulos EB, Ladanvi M: Donor leukocyte infusions as treatment of Epstein-Barr virus lymphoproliferative disorders (EBV-LPD) in recipients of unrelated and related allogeneic transplants. Blood 82:214a, 1993 (suppl 1, abstr)
36. Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D,Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar, Hale G, Waldman H, Steinberg SM, Slavin S: T-cell-depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506, 1995